Compare AbCellera Biologics Inc (ABCL) vs Bank of New York Mellon Corp (BNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Bank of New York Mellon Corp — how do they compare? AbCellera Biologics Inc trades at $10.03 (market cap $2.99B), while Bank of New York Mellon Corp trades at $162.83 (market cap $108.78B). The key difference: Bank of New York Mellon Corp is far larger — about 36.4× AbCellera Biologics Inc's market cap, and Bank of New York Mellon Corp pays a 1.38% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | BNY | |
|---|---|---|
Market Cap | $2.99B | $108.78B |
Sector | Health | Financials |
52-Week High | $9.76 | $162.35 |
52-Week Low | $2.78 | $101.00 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.
The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.
BNY stock trades at $162.92, up 2.18% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.46 beating estimates and consistent revenue growth from $19.76B in 2025 to $21.0B projected for 2026. Analyst sentiment remains positive with 10 buy ratings and a $170.36 consensus price target, supported by recent digital transfer agency expansion and blockchain infrastructure collaborations.
Outlook remains favorable with earnings momentum and digital innovation driving growth, though elevated RSI levels suggest near-term consolidation risk. The stock offers 4.6% upside to consensus target with strong institutional support, balanced by competitive pressures in custody banking and interest rate sensitivity as key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Bank of New York Mellon Corp
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with about $41.1 trillion in under custody and administration (as of Dec. 31, 2020), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.2 trillion in assets.
Read more on BNY →
